AI Analysis | Feedback

An early-stage Amgen for targeted brain cancer radiation therapy.

A startup Novartis, specializing in one innovative radiopharmaceutical for brain cancer.

A biotech similar to an early Moderna, but developing targeted radiation treatments for brain cancer.

AI Analysis | Feedback

• Rhenium-186 NanoLiposome (RNL): An investigational targeted radiotherapeutic in clinical development for the treatment of recurrent glioblastoma and other solid tumors.

AI Analysis | Feedback

Plus Therapeutics (PSTV) is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. As a clinical-stage company, it does not currently have any commercially approved products on the market that generate sales revenue.

Therefore, Plus Therapeutics does not have "major customers" in the traditional sense who purchase its products or services. Its primary activities revolve around conducting clinical trials, research and development, and seeking regulatory approvals for its investigational drug candidates.

Instead of customers, the company primarily interacts with and relies on funding from:

• Clinical Trial Sites: These are typically hospitals, universities, and research institutions that collaborate on and conduct the clinical trials for Plus Therapeutics' investigational drug candidates. These entities are partners in the development process rather than direct customers purchasing a product.
• Investors: Various institutional and individual investors who provide capital through equity financing to fund the company's extensive research, development, and operational activities.
• Grant-making Organizations: Entities such as the Cancer Prevention and Research Institute of Texas (CPRIT), which provide non-dilutive grants to support specific research and development programs.

If and when Plus Therapeutics receives commercial approval for a product, its customers would typically become hospitals, clinics, and pharmacies, who would then procure the medication for administration to patients.

AI Analysis | Feedback

AI Analysis | Feedback

Marc Hedrick, MD, MBA - President and CEO

Dr. Marc Hedrick has served as President and CEO of Plus Therapeutics, Inc. since 2014. He is also a Director of CNSide Diagnostics since February 2025. Prior to joining Plus Therapeutics, Dr. Hedrick held several executive leadership roles, including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. He also previously co-founded StemSource Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon, and was a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). He also co-directed the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas, and an MBA from The Anderson School at UCLA in 2005.

Andrew Sims, CPA - Vice President and Chief Financial Officer

Andrew Sims has been the Vice President and Chief Financial Officer at Plus Therapeutics, Inc. since 2020. Mr. Sims has a pattern of managing companies backed by private equity firms, having previously held CFO roles at several such companies. His experience includes mergers and acquisitions, corporate capitalization, and building teams for global growth. Prior to Plus Therapeutics, Mr. Sims was a Partner at Mazars, a global accounting and advisory firm, where he audited and advised public clients, including healthcare companies, and was the lead partner on over 50 acquisitions ranging from $5 million to $4 billion. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales.

Russ Havranek, MS MBA - EVP, Commercial and Corporate Strategy

Russ Havranek is the Executive Vice President of Commercial and Corporate Strategy at Plus Therapeutics.

Michael Rosol, PhD - Chief Development Officer

Dr. Michael Rosol has been the Chief Development Officer of Plus Therapeutics since February 2025. Prior to this, he was the Chief Medical Officer and Senior Vice President at Navidea Biopharmaceuticals and also worked at Novartis Pharmaceuticals.

Russell Bradley - President and General Manager, CNSide Diagnostics

Russell Bradley was appointed President and General Manager of Plus Therapeutics' wholly-owned subsidiary, CNSide Diagnostics, LLC, in February 2025. He also serves on the CNSide Board of Directors. Mr. Bradley brings over 30 years of leadership experience in diagnostics from companies such as Abbott Laboratories, Luminex, and Beckman Coulter.

AI Analysis | Feedback

1. Financial Instability and Need for Further Capital: Plus Therapeutics operates with substantial ongoing losses and a high cash burn rate, leading to a limited cash runway. The company has explicitly expressed "substantial doubt about continuing as a going concern due to ongoing losses and funding needs". This necessitates continuous efforts to raise additional capital, primarily through equity financing, which poses a constant threat of significant shareholder dilution. For example, in Q3 2025, the company reported an operating loss of $4.5 million and a net loss of $4.4 million, with only $16.6 million in cash and investments, suggesting a limited operational runway without further funding.
2. Clinical Development and Regulatory Approval Risk: As a clinical-stage company, Plus Therapeutics' success hinges on the successful completion of clinical trials for its lead product candidates, REYOBIQ™ and CNSide®, and subsequent regulatory approvals. There is an inherent risk that clinical trials may fail to demonstrate sufficient safety or efficacy, encounter delays, or face unforeseen challenges. Regulatory hurdles, uncertain payer adoption, and pricing pressures could also hinder the timely commercialization of products and limit future revenue growth and profitability.
3. Nasdaq Listing Compliance Risk: Plus Therapeutics has received notifications of deficiency from Nasdaq regarding compliance with listing rules, including the minimum bid price requirement. While the company has received extensions to regain compliance, failure to meet these requirements could result in the delisting of its common stock from the Nasdaq Capital Market. Such an event would negatively impact the stock's liquidity, investor confidence, and the company's ability to raise capital in the future.

AI Analysis | Feedback

AI Analysis | Feedback

Plus Therapeutics (NASDAQ: PSTV) is a clinical-stage pharmaceutical company focused on developing radiotherapeutics for rare and difficult-to-treat cancers. Its lead product candidate, Rhenium-186 NanoLiposome (186RNL), also known as REYOBIQ, is being developed for several indications, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Addressable Markets:

• Recurrent Glioblastoma (GBM): The global recurrent glioblastoma multiforme treatment market was valued at approximately $2.20 billion in 2024 and is projected to reach $4.86 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.1% from 2026 to 2032. The United States represents the largest market for its treatment.
• Leptomeningeal Metastases (LM): The total leptomeningeal metastases treatment market size was approximately $1.7 billion in 2024 in the leading markets (the U.S., EU4 (Germany, Italy, France, and Spain), the U.K., and Japan). The United States alone accounts for 60% of this market size.
• Pediatric Brain Tumors: The global pediatric brain tumor market size was approximately $1.3 billion in 2024 and is expected to grow to $1.81 billion in 2029 at a CAGR of 6.8%. Another estimate values the global market at approximately $1.2 billion in 2023, projected to reach around $2.4 billion by 2032, growing at a CAGR of 7.2%. North America was the largest region in the pediatric brain tumors market in 2024, accounting for approximately 40% of the global market share in 2023.

AI Analysis | Feedback

1. Commercialization of the CNSide Diagnostic Platform: Plus Therapeutics plans a commercial rollout of its CNSide cerebrospinal fluid diagnostic platform in the second half of 2025, beginning in Texas and expanding to additional states in late 2025 and 2026. The company has already secured a national coverage agreement with UnitedHealthcare for CNSide, effective September 2025. Analysts project CNSide to generate approximately $1 million in revenue in 2025, with meaningful contributions expected in fiscal year 2026, targeting a United States total addressable market of about $6 billion annually.
2. Advancement and Potential Commercialization of REYOBIQ for Leptomeningeal Metastases (LM): Plus Therapeutics' lead drug candidate, REYOBIQ (Rhenium-186 NanoLiposome), is undergoing clinical trials for leptomeningeal metastases. Positive preliminary results from the ReSPECT-LM study have shown a clinical benefit rate above 75%, reductions in circulating tumor cells, and a favorable median overall survival of 12 months compared to historical data of approximately four months. REYOBIQ has received FDA Fast Track and Orphan Drug designations, and enrollment in the ReSPECT-LM Dose Optimization Trial is ongoing. The company intends to complete an end-of-Phase 1 meeting with the FDA to define the path to approval, particularly for LM associated with breast cancer.
3. Advancement of REYOBIQ for Pediatric Brain Cancer (ReSPECT-PBC trial): The U.S. Food and Drug Administration (FDA) has cleared Plus Therapeutics' Investigational New Drug (IND) application for REYOBIQ for the treatment of pediatric patients with high-grade glioma and ependymoma. This ReSPECT-PBC trial is supported by a $3 million grant from the U.S. Department of Defense, spanning a three-year period, which helps fund the development that could lead to future product revenue.
4. Advancement of REYOBIQ for Recurrent Glioblastoma (ReSPECT-GBM trial): The company is focused on completing enrollment in its ReSPECT-GBM trial, with Phase II enrollment expected to conclude by the end of 2025. Successful completion of these trials and subsequent regulatory approvals would open up another significant market for REYOBIQ.
5. Grant Funding: While not a commercial product, significant non-dilutive grant funding from entities such as the Cancer Prevention and Research Institute of Texas (CPRIT) and the U.S. Department of Defense continues to be a notable revenue source for Plus Therapeutics, supporting its clinical development programs. The company anticipates $6 million to $8 million in grant revenue for 2025.

AI Analysis | Feedback

Share Repurchases

• In August 2022, Plus Therapeutics authorized a share repurchase program to buy back up to $2.0 million of its outstanding common stock.
• In October 2023, the company approved another share repurchase program, authorizing the repurchase of up to $500,000 of its outstanding common stock.

Share Issuance

• The company experienced significant capital raises, including sales under a Lincoln Park Purchase Agreement, which contributed to year-to-date financing cash inflows of $27.5 million as of Q3 2025.
• Plus Therapeutics' shares outstanding have increased substantially, with a reported 682.06% increase in one year, reaching 137.43 million shares outstanding.

Capital Expenditures

• Over the last 12 months, capital expenditures for Plus Therapeutics were approximately $48,000.
• These expenditures are likely focused on supporting key development, manufacturing, and preclinical activities within their laboratories and state-of-the-art clean rooms.